What is the price target for CALT stock?
13 analysts have analysed CALT and the average price target is 45.37 USD. This implies a price increase of 13.42% is expected in the next year compared to the current price of 40.0001.
Calliditas Therapeutics AB (CALT) Forecast, Price Target & Analyst Ratings
NASDAQ:CALT • US13124Q1067
Current stock price
40.0001 USD
-0.16 (-0.4%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Calliditas Therapeutics AB (CALT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Nov 11, 2024
- Period
- Q3 / 2024
- EPS Estimate
- SEK2.49
- Revenue Estimate
- 547.4M
Price Target Details & History
Consensus Price Target and Range
Mean target
$45.37
Upside
+ 13.42%
From current price of $40.00 to mean target of $45.37, Based on 13 analyst forecasts
Low
$34.95
Median
$43.67
High
$60.56
Price Target Revisions
1 Month
6.89%
3 Months
6.52%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for CALT. The average price target is 45.37 USD. This implies a price increase of 13.42% is expected in the next year compared to the current price of 40.0001.
The average price target has been revised upward by 6.52% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.54%
CALT was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about CALT.
In the previous month the buy percentage consensus was at a similar level.
CALT was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-05-31 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-05-28 | Stifel | Downgrade | Buy -> Hold |
| 2024-05-28 | Jefferies | Downgrade | Buy -> Hold |
| 2024-05-28 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-05-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-18 | Guggenheim | Maintains | Neutral -> Neutral |
| 2023-06-20 | HC Wainwright & Co. | Initiate | Buy |
| 2023-03-01 | Guggenheim | Initiate | Neutral |
| 2023-02-24 | Citigroup | Maintains | Buy |
| 2021-12-20 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Nov 11, 2024
- Period
- Q3 / 2024
- EPS Estimate
- SEK2.49
- Revenue Estimate
- 547.4M
- Revenue Q2Q
- 85.82%
- EPS Q2Q
- 139.91%
- Number of Analysts
- 7
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
2.11%
EPS (1 Month)
-0.67%
EPS (3 Months)
61.18%
Next Earnings Summary
CALT is expected to report earnings on 11/11/2024. The consensus EPS estimate for the next earnings is 2.49 USD and the consensus revenue estimate is 547.40M USD.
The next earnings revenue estimate has been revised upward by 2.11% in the past 3 months.
Full Analyst Estimates 2024 - 2031
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 229.347M 26,141.08% | 802.879M 250.07% | 1.207B 50.32% | 2.01B 66.54% | 3.275B 62.94% | 4.676B 42.78% | 6.128B 31.05% | 6.353B 3.67% | 4.699B -26.03% | 3.844B -18.20% | 3.603B -6.27% | |
| EBITDA YoY % growth | N/A -20.10% | -401.897M 17.40% | -341.857M 14.94% | 124.94M 136.55% | 1.065B 752.41% | 2.036B 91.17% | 5.303B 160.46% | 5.682B 7.15% | 3.944B -30.59% | 2.055B -47.90% | N/A | |
| EBIT YoY % growth | -524.605M -37.26% | -414.81M 20.93% | -390.583M 5.84% | 129.78M 133.23% | 1.007B 675.93% | 1.814B 80.14% | 3.332B 83.68% | 3.265B -2.01% | 2.324B -28.82% | 1.727B -25.69% | 1.7B -1.56% | |
| Operating Margin | -228.74% | -51.67% | -32.36% | 6.46% | 30.75% | 38.79% | 54.37% | 51.39% | 49.46% | 44.93% | 47.18% | |
| EPS YoY % growth | N/A -39.33% | N/A 20.70% | -17.25 -14.44% | 4.66 127.00% | 38.16 719.41% | 79.65 108.75% | 203.73 155.79% | 278.63 36.76% | N/A | N/A | N/A |
All data in SEK
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | 2.49 139.91% | 6.73 1,095.67% |
| Revenue Q2Q % growth | 547.4M 85.82% | 697.1M 54.38% |
| EBITDA Q2Q % growth | 87.55M 722.61% | 242.74M 361.86% |
| EBIT Q2Q % growth | 67.692M 142.42% | 208.32M 398.80% |
All data in SEK
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
87.75%
EPS Next 5 Year
78.56%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
58.16%
Revenue Next 5 Year
39.98%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
83.96%
EBIT Next 5 Year
69.01%
Calliditas Therapeutics AB / CALT Forecast FAQ
When does Calliditas Therapeutics AB (CALT) report earnings?
Calliditas Therapeutics AB (CALT) will report earnings on 2024-11-11, before the market open.
What are the consensus estimates for Calliditas Therapeutics AB (CALT) next earnings?
The consensus EPS estimate for the next earnings of Calliditas Therapeutics AB (CALT) is 2.49 USD and the consensus revenue estimate is 547.40M USD.
What is the consensus rating for Calliditas Therapeutics AB (CALT) stock?
The consensus rating for Calliditas Therapeutics AB (CALT) is 81.5385 / 100 . This indicates that analysts generally have a positive outlook on the stock.